RBC Capital resumed coverage of Illumina (ILMN) with an Outperform rating and $170 price target The firm states that its constructive view on the stock is underpinned by building clinical momentum and fading competitive concerns. With clinical momentum building and competitive risks receding, the firm sees a favorable risk/reward for Illumina at current levels, RBC added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN: